Recently, the Shanghai Municipal Science and Technology Commission released the "Notice on Project Approval for the 2025 'Science and Technology Innovation Action Plan' Biomedical Innovation Development Program." Shanghai MAaGI Medical Technology Co., Ltd.’s proposed project, "Development of a Tumor Interventional Immunotherapy System with Multi-physics Field Dynamic Modulation," has been successfully approved for funding.

The Shanghai 2025 "Science and Technology Innovation Action Plan" Biomedical Innovation Development Program, implemented by the Shanghai Municipal Science and Technology Commission, aims to support enterprises in breaking through key technologies, accelerate the transformation of biomedical scientific and technological achievements, and contribute to Shanghai's development as a globally influential science and technology innovation center.

This approval marks another authoritative government recognition of MAaGI Medical's innovative capabilities in the field of interventional immunotherapy.

MAaGI  Medical's independently developed national innovative medical device—the Multimodal Tumor Thermal Therapy System—has demonstrated outstanding safety and efficacy in clinical applications and has received multiple prestigious awards. The newly approved project, "Development of a Tumor Interventional Immunotherapy System with Multi-physics Field Dynamic Modulation," will build upon the company's thermophysical immunotherapy platform. Through iterative improvements in hardware and algorithms, the project aims to overcome technical bottlenecks in solid tumor interventional therapy, achieve synergistic multi-physics field modulation of the tumor immune microenvironment, and provide patients with a more precise and durable minimally invasive treatment option.

This support from Shanghai's 2025 "Science and Technology Innovation Action Plan" Biomedical Innovation Development Program injects strong momentum into the subsequent R&D and iteration of M-Jay Medical's products. The company will continue to advance integrated innovation across industry, academia, research, and clinical practice, accelerating the breakthrough in domestic production of interventional immunotherapy equipment, and benefiting patients with new quality productive forces.